HDL hypothesis: Where do we stand now?

Current Atherosclerosis Reports

Volumn 16, Issue 4, 2014, Pages

  Tariq, Sayed M ^a   Sidhu, Mandeep S ^b   Toth, Peter P ^c   Boden, William E ^b  

^a ALBANY MEDICAL CENTER   (United States)

^b STRATTON VA MEDICAL CENTER   (United States)

^c UNIVERSITY OF ILLINOIS   (United States)

Author keywords

AIM HIGH; Atherosclerosis; Coronary artery disease; HDL; HPS2 THRIVE; Niacin

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; EZETIMIBE; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAROPIPRANT; NICOTINIC ACID; PLACEBO; SIMVASTATIN; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY DISEASE; DRUG EFFICACY; DYSLIPIDEMIA; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; LIPOPROTEIN METABOLISM; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL VASCULAR DISEASE; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SECONDARY PREVENTION; TRANSIENT ISCHEMIC ATTACK; CLINICAL TRIAL (TOPIC); METABOLISM; REVIEW;

ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CLINICAL TRIALS AS TOPIC; CORONARY ARTERY DISEASE; HUMANS; RISK FACTORS;

EID: 84895569449     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-014-0398-0     Document Type: Article

References (45)

1. National Cholesterol Education Program (NCEP) Expert Panel on Detection, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation. 2002;106 (25):3143- 421. 2.• Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013. doi:10.1016/j.jacc. 2013.11.002.
2. Ridker PM, Cook NR. Statins: new American guidelines for prevention of cardiovascular disease. Lancet. 2013;382 (9906):1762-5.
3. Kannel WB, Dawber TR, Friedman GD, et al. Risk factors in coronary heart disease. An evaluation of several serum lipids as predictors of coronary heart disease; The Framingham Study. Ann Intern Med. 1964;61:888-99.
4. Castelli WP. Cholesterol and lipids in the risk of coronary artery disease-the Framingham Heart Study. Can J Cardiol. 1988;4 (Suppl A):5A-10A.
5. The Coronary Drug Project Research Group. JAMA. 1972;221 (8): 918.
6. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA. 1975;231 (4):360-81.
7. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in coronary drug project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8 (6):1245-55. (Pubitemid 17208898)
8. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto Jr AM, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-207.
9. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-35. (Pubitemid 40471450)
10. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-9.
11. Sacks FM, PfefferMA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-9. (Pubitemid 26338729)
12. The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339: 1349-57.
13. Jafri H, Alsheikh-Ali AA, Karas RH. Meta-analysis: statin therapy does not alter the association between low levels of high-density lipoprotein cholesterol and increased cardiovascular risk. Ann Intern Med. 2010;153 (12):800-8.
14. Bezafibrate Infarction Prevention (BIP) study. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation. 2000;102 (1):21-7.
15. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97 (18):1837-47. (Pubitemid 28213628)
16. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med. 1977;62 (5):707-14. (Pubitemid 8110784)
17. Rubins HB, Robins SJ, Collins D, et al. Distribution of lipids in 8, 500 men with coronary artery disease. Department of Veterans Affairs HDL Intervention Trial Study Group. Am J Cardiol. 1995;75 (17):1196-201.
18. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. For the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999;341 (6):410-8. 20. (Pubitemid 29362514)
19. Armitage J et al. HPS2-THRIVE: randomized placebo controlled trial of ER Niacin and laropiprant in 25, 673 patients with preexisting cardiovascular disease. Eur Heart J. 2013;34 (17):1279-
20. Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367 (22):2089-99.
21. Wolfram RM, Brewer HB, Xue Z, et al. Impact of low high-density lipoproteins on in-hospital events and one-year clinical outcomes in patients with non-ST-elevation myocardial infarction acute coronary syndrome treated with drug-eluting stent implantation. Am J Cardiol. 2006;98 (6):711-7. (Pubitemid 44300998)
22. Acharjee S, Roe MT, Amsterdam EA, et al. Relation of admission high-density lipoprotein cholesterol level and in-hospital mortality in patients with acute non-ST segment elevation myocardial infarction (from the National Cardiovascular Data Registry). Am J Cardiol. 2013;112 (8):1057-62.
23. BodenWE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356 (15):1503-16. (Pubitemid 46588415)
24. Acharjee S, Boden WE, Hartigan PM, et al. Low levels of highdensity lipoprotein cholesterol and increased risk of cardiovascular events in stable ischemic heart disease patients: a post-hoc analysis from the COURAGE Trial. J Am Coll Cardiol. 2013;62:1826-33. doi:10.1016/j.jacc.2013.07.051.
25. Fisher EA, Feig JE, Hewing B, Hazen SL, Smith JD. High-density lipoprotein function, dysfunction, and reverse cholesterol transport. Arterioscler Thromb Vasc Biol. 2012;32 (12):2813-20.
26. Cuchel M, Rader DJ. Macrophage reverse cholesterol transport: key to the regression of atherosclerosis? Circulation. 2006;113: 2548-55. (Pubitemid 43948034)
27. Brewer Jr HB, Remaley AT, Neufeld EB, Basso F, Joyce C. Regulation of plasma high-density lipoprotein levels by the ABCA1 transporter and the emerging role of high-density lipoprotein in the treatment of cardiovascular disease. Arterioscler Thromb Vasc Biol. 2004;24:1755-60. (Pubitemid 39350289)
28. Rigotti A, Miettinen HE, Krieger M. The role of the high-density lipoprotein receptor SR-BI in the lipid metabolism of endocrine and other tissues. Endocr Rev. 2003;24:357-87. (Pubitemid 36724375)
29. Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, et al. Cholesterol efflux capacity, highdensity lipoprotein function, and atherosclerosis. N Engl J Med. 2011;364:127-35.
30. Bonow, Mann, Zipes, Libby. Braunwald's heart disease: A textbook of cardiovascular medicine, vol. 1. 9th ed. Philadelphia: Saunders Elsevier; 2012. p. 975-82.
31. Toth PP. Model of reverse cholesterol transport torcetrapib and atherosclerosis: what happened and where do we go from here? Futur Lipidol. 2007;2 (3):277-84.
32. Hovingh GK, deGroot E, van der SteegW, et al. Inherited disorders of HDL metabolism and atherosclerosis. Curr Opin Lipidol. 2005;16 (2):139-45. (Pubitemid 40515887)
33. Sirtori CR, Calabresi L, Franceschini G, et al. Cardiovascular status of carriers of the apolipoprotein A-I (Milano) mutant: the Limone sul Garda study. Circulation. 2001;103 (15):1949-54. (Pubitemid 32322221)
34. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357 (21):2109-22. (Pubitemid 350146106)
35. Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification (REVEAL). ClinicalTrials.gov Identifier: NCT01252953.
36. A Study of Evacetrapib in High-Risk Vascular Disease (ACCELERATE). ClinicalTrials.gov Identifier:NCT01687998.
37. Wu BJ, Yan L, Charlton F, et al. Evidence that Niacin Inhibits acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipids. Arterioscler Thromb Vasc Biol. 2010;30 (5):968-75.
38. Kuvin JT, Patel AR, Sidhu MS, et al. Relationship between high density lipoprotein (HDL) cholesterol and peripheral vasomotor function. Am J Cardiol. 2003;92 (3):275-9. (Pubitemid 36897708)
39. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366 (9500):1849-61.
40. The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563-74.
41. Manninen V, EloMO, FrickMH, et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA. 1988;260 (5):641-51.
42. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345 (22):1583-92. (Pubitemid 33126837)
43. BodenWE, Sidhu MS, Toth PP. The Therapeutic Role of Niacin in Dyslipidemia Management. J Cardiovasc Pharmacol Ther. 2014;19 (2):141-58.
44. Landmesser U. The difficult search for a 'partner' of statins in lipidtargeted prevention of vascular events: the re-emergence and fall of niacin. Eur Heart J. 2013;34 (17):1254-7. doi:10.1093/eurheartj/eht055.
45. van de Woestijne AP, van der Graaf Y, Liem AH, Cramer MJM, Westerink J, Visseren FLJ, et al. Low high-density lipoprotein cholesterol is not a risk factor for recurrent vascular events in patients with vascular disease on intensive lipid-lowering medication. J Am Coll Cardiol. 2013;62 (20):1834-41. doi:10.1016/j.jacc. 2013.04.101.